Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib + Docetaxel in Advanced HCC and Biliary Tract Carcinomas
NCT00532441Phase 2Terminated
- Start
- Sep 2007
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in hepatocellular carcinoma (HCC), biliary tract cancer (BTC). Started Sep 2007; status: terminated.
02
Drugs
erlotinib
03
Conditions
hepatocellular carcinoma (HCC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT00532441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00532441.